Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia

详细信息    查看全文

• 作者：Sunao Kojima ; MD ; PhD ; FJCC^a ; ^{kojimas@kumamoto-u.ac.jp} ; Kunihiko Matsui ; MD ; PhD^a ; Hisao Ogawa ; MD ; PhD ; FJCC^b ; Hideaki Jinnouchi ; MD ; PhD^c ; Shinya Hiramitsu ; MD^d ; Takahiro Hayashi ; MD ; PhD ; FJCC^e ; Naoto Yokota ; MD ; PhD^f ; Naoki Kawai ; MD^g ; Eiichi Tokutake ; MD^h ; Kazuaki Uchiyama ; MD ; PhDⁱ ; Masahiro Sugawara ; MD ; PhD^j ; Hirokazu Kakuda ; MD^k ; Yutaka Wakasa ; MD^l ; Hisao Mori ; MD ; PhD^m ; Ichiro Hisatome ; MD ; PhD ; FJCCⁿ ; Masako Waki ; MD ; PhD^o ; Yusuke Ohya ; MD ; PhD ; FJCC^p ; Kazuo Kimura ; MD ; FJCC^q ; Yoshihiko Saito ; MD ; FJCC^r ; on behalf of the Febuxostat for Cerebral ; Cardiorenovascular Events Prevention Study (FREED) investigators
• 关键词：Febuxostat ; Hyperuricemia ; Elderly patient ; Cerebral disease ; Cardiorenal disease
• 刊名：Journal of Cardiology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：69
• 期：1
• 页码：169-175
• 全文大小：402 K
• 卷排序：69

文摘

Since uric acid is associated with cardiovascular and renal disease, a treatment to maintain blood uric acid level may be required in patients with hyperuricemia. This study aims to evaluate preventive effects of febuxostat, a selective xanthine oxidase inhibitor, on cerebral, cardiovascular, and renal events in patients with hyperuricemia compared to conventional treatment.Methods and resultsThis study is a prospective randomized open-label blinded endpoint study. Patient enrolment was started in November 2013 and was completed in October 2014. The patients will be followed for at least 3 years. The primary endpoint is a composite of cerebral, cardiovascular, and renal events, and all deaths including death due to cerebral, cardiovascular, and renal disease, new or recurring cerebrovascular disease, new or recurring non-fatal coronary artery disease, cardiac failure requiring hospitalization, arteriosclerotic disease requiring treatment, renal impairment, new atrial fibrillation, and all deaths other than cerebral or cardiovascular or renal disease. These events will be independently evaluated by the Event Assessment Committee under blinded information regarding the treatment group. The study was registered at ClinicalTrials.gov with the identifier NCT01984749.